Praziquantel Bioequivalence Study

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

July 6, 2018

Study Completion Date

July 6, 2018

Conditions
Healthy
Interventions
DRUG

Cisticid

Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).

DRUG

Biltricide

Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Trial Locations (1)

58249

Clínica de Enfermedades Crónicas y de Procedimientos Especiales, Sociedad Civil (SC), México

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03437447 - Praziquantel Bioequivalence Study | Biotech Hunter | Biotech Hunter